Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions (Nasdaq: INBS) launched a validation study on April 20, 2026 to accelerate its Intelligent Fingerprinting Drug Screening System from a current ~10-minute result to a target sub-3-minute (two-minute goal) analysis time.

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) launched a validation study on April 20, 2026 to accelerate its Intelligent Fingerprinting Drug Screening System from a current ~10-minute result to a target sub-3-minute (two-minute goal) analysis time.

The study is preliminary; INBS is deployed in U.S. Forensic Use Only settings and is pursuing FDA 510(k) clearance for opiate codeine. The company cites a U.S. roadside testing market of $1.17B (2023) projected to $1.62B by 2030 and a global drug screening TAM of $16.7B through 2030.

Positive

• Targeting sub-3-minute analysis vs current 10-minute test
• Deployed in U.S. Forensic Use Only market
• Pursuing FDA 510(k) clearance for opiate codeine
• U.S. roadside market: $1.17B (2023) to $1.62B by 2030
• Global drug screening TAM estimated at $16.7B through 2030

Negative

• Validation study is in a preliminary phase, outcome uncertain
• No current FDA clearance—limits U.S. commercial use
• Targeted sub-3-minute performance is not yet confirmed

Argus Apr 20 session

+10.15% close to close Open Argus

Details

News Market Reaction – INBS

On Apr 20, the day this news came out, INBS closed 10.15% above the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Market Context

On Apr 20, the day this news came out, the stock closed 10.2% above the previous close. A strong pos...

Analysis

On Apr 20, the day this news came out, the stock closed 10.2% above the previous close. A strong positive reaction aligns with INBS highlighting faster, sub-3-minute drug screening and access to a U.S. roadside testing market projected at $1.62 billion by 2030 and a global market of $16.7 billion. However, past news often saw selling despite positive developments, and an effective resale shelf with 6,896,550 registered shares plus ATM capacity may pose ongoing overhang and dilution risk if used aggressively.

Key Figures

Current test time: 10 minutes Target test time: under 3 minutes Sample collection time: under 1 minute +5 more

Current test time

10 minutes

Current time-to-result for INBS drug screening system

Target test time

under 3 minutes

Validation study goal for analysis time

Sample collection time

under 1 minute

Current fingerprint sample collection time

U.S. roadside market 2023

$1.17 billion

U.S. roadside drug testing market size in 2023

U.S. roadside market 2030

$1.62 billion

Projected U.S. roadside drug testing market by 2030

Roadside CAGR

4.71%

Compound annual growth rate for U.S. roadside drug testing to 2030

Global drug screening CAGR

14%

Projected CAGR for global drug screening products market through 2030

Global addressable market 2030

$16.7 billion

Projected global drug screening products market by 2030

Historical Context

5 past events · Latest: Apr 02

5 events

1. Apr 02

   Clinical program progress

   24h Move

   -11.9%

   Completion of codeine cut-off study and launch of multi-site FDA-support trials.

2. Mar 26

   IP/patent expansion

   24h Move

   +1.5%

   Eighth European patent granted, strengthening fingerprint drug screening IP.

3. Feb 25

   Manufacturing scale-up

   24h Move

   -4.3%

   First shipment from new manufacturing partner, boosting capacity and margins.

4. Feb 24

   Commercial partnership

   24h Move

   -2.6%

   Partnership with Bouygues UK to roll out fingerprint drug screening on 13 sites.

5. Feb 12

   Earnings and financing

   24h Move

   -6.7%

   Record Q2 revenue growth and $10M private placement to fund operations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k) clearance, forensic use only, compound annual growth rate, point-of-collection

4 terms

510(k) clearance regulatory

"remains focused on securing FDA 510(k) clearance of its Intelligent Fingerprinting Drug"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

forensic use only regulatory

"INBS's system is already deployed in the Forensic Use Only market in the U.S."

A label meaning a test, device, or kit is intended only for legal, investigative, or quality-control purposes and not for diagnosing or treating patients. Think of it like a tool stamped “for museum display only” — it may prove something in court or help investigators, but it cannot be used by doctors for medical decisions; that limitation affects who can buy it, how it’s reimbursed, and its commercial value.

compound annual growth rate financial

"growing at a compound annual growth rate of 4.71%1."

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

point-of-collection technical

"non-invasive, point-of-collection solutions that are easy to administer."

The point-of-collection is the physical location or moment where a sample, data point, payment or item is gathered from a person or device — for example a clinic window, mobile testing van, retail kiosk, home kit pickup or digital checkout screen. For investors it matters because where and how collection happens affects operating costs, speed, regulatory requirements and customer reach; think of it like a store’s checkout counter that shapes convenience, compliance and the cost to serve customers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes 

U.S. Roadside drug testing market projected to reach $1.62 billion by 2030

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System.

The study aims to improve the already rapid time-to-result of INBS's drug screening technology, which collects samples in under a minute and provides results within ten minutes at the point of collection. Faster results will enable INBS to target the global roadside drug testing market with a first-in-class solution.

"Speed matters in drug screening and is critical for roadside law enforcement,” said Harry Simeonidis, President and CEO at INBS. “Moving from a ten-minute test to under three minutes changes the entire value equation for our customers. This validation study aims to confirm our encouraging preliminary findings and advance us toward our two-minute test goal.”

In the U.S. alone, roadside drug testing was valued at $1.17 billion in 2023 and is projected to reach $1.62 billion by 2030, growing at a compound annual growth rate of 4.71%¹. The rise in prescription medications, recreational marijuana, and illicit drugs has created a surge in drug-related accidents and fatalities. Law enforcement agencies are intensifying efforts to combat impaired driving, creating demand for advanced testing solutions that deliver quick, accurate field results. INBS's system is already deployed in the Forensic Use Only market in the U.S., and enhanced speed would further strengthen the technology’s positioning as states expand drug testing programs following marijuana legalization and increased substance abuse concerns.

Faster analysis times have the potential to transform roadside drug testing in the same way that breathalyzers revolutionized alcohol enforcement. Increased testing throughput will enable law enforcement to screen more drivers, improving road safety and potentially saving lives. In addition to roadside applications, accelerated testing would further expand INBS's access to other high-value verticals beyond its established workplace testing business, which currently operates outside the United States, including drug treatment and rehabilitation, and the consumer health market.

The wider global drug screening products market is projected to grow at a compound annual growth rate of approximately 14% through 2030, reaching an estimated addressable market of $16.7 billion². Time-to-result is increasingly valued as law enforcement and government agencies favor fast, non-invasive, point-of-collection solutions that are easy to administer.

INBS continues to navigate the regulatory pathway and remains focused on securing FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine, which will enable broader use in the U.S. market beyond current Forensic Use Only settings. The U.S. market represents a multi-billion-dollar opportunity spanning workplace testing, criminal justice, law enforcement, and substance abuse treatment and enhanced testing speed would provide a compelling competitive advantage as the Company pursues planned U.S. market entry.

The validation study is in its preliminary phase.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. 

For more information, visit: https://ibs.inc/ 

Forward-Looking Statements 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  

Company Contact 
Intelligent Bio Solutions Inc.  
info@ibs.inc

Investor & Media Contact  
Valter Pinto, Managing Director  
KCSA Strategic Communications  
PH: (212) 896-1254  
INBS@kcsa.com 

________________________________
_{Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.}

_{¹ Grand View Research 2023. U.S. Roadside Drug Testing Market (2024 - 2030). Available at: https://www.grandviewresearch.com/industry-analysis/us-roadside-drug-testing-market-report}

_{² Research and Markets 2026. Drug screening – Global Strategic Business Report. Available at: https://www.researchandmarkets.com/reports/4804177/drug-screening-global-strategic-business-report}

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Intelligent Bio Solutions (INBS) validating in the April 20, 2026 study?

INBS is validating a faster time-to-result, aiming for sub-3-minute drug screening. According to the company, the study seeks to shorten the current ~10-minute Intelligent Fingerprinting result toward a two-minute goal to expand roadside use.

How could the INBS speed improvement affect U.S. roadside testing market (INBS)?

Faster results could increase throughput and law enforcement adoption at roadside. According to the company, U.S. roadside testing was $1.17B in 2023 and may reach $1.62B by 2030, creating a larger addressable opportunity.

Has Intelligent Bio Solutions (INBS) received FDA clearance for its drug screening system?

No—INBS is currently pursuing FDA 510(k) clearance for opiate codeine detection. According to the company, clearance remains pending and is required for broader U.S. market use beyond Forensic Use Only settings.

Where is INBS's Intelligent Fingerprinting system currently deployed and allowed?

The system is deployed in the U.S. Forensic Use Only market today. According to the company, broader commercial and roadside deployment in the U.S. depends on successful validation and regulatory clearance.

What market size does INBS cite for the global drug screening opportunity?

INBS cites an estimated global drug screening market of $16.7B through 2030. According to the company, the wider market is projected to grow at about a 14% compound annual growth rate to 2030.

What is the current status and timing of the INBS validation study?

The validation study is in a preliminary phase as of April 20, 2026. According to the company, the study will confirm preliminary findings and advance progress toward their two-minute test objective.